The current state of gene therapy in managing neovascular macular degeneration

Neovascular age-related macular degeneration (nAMD), also known as wet AMD, is a major cause of vision loss among older adults. Traditional treatments involve frequent intravitreal injections of anti-VEGF drugs, which can be burdensome for patients and health care systems. Gene therapy offers a promising alternative by potentially providing long-lasting effects from a single treatment. This article explores the advancements in gene therapy for nAMD, focusing on the work of REGENXBIO, 4D Molecular Therapeutics (4DMT), and Adverum Biotechnologies.